Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
upadacitinib + ustekinumab
- Development stage
- Phase 4
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
Dual-targeted therapy combining upadacitinib (a selective JAK1 inhibitor) and ustekinumab (an IL-12/IL-23 inhibitor) used primarily for treating refractory Crohn's disease and patients with co-existing extraintestinal manifestations. This combination approach targets multiple inflammatory pathways simultaneously and has shown efficacy in patients who have failed multiple previous biologic therapies.
- Brand names
- Stelara (ustekinumab)Wezlana (ustekinumab)Imuldosa (ustekinumab)Otulfi (ustekinumab)Pyzchiva (ustekinumab)Rinvoq (upadacitinib)
02
Targets
Beyond the preview
Go deeper on upadacitinib + ustekinumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on upadacitinib + ustekinumab.